Repository logo
 
Publication

Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a While

2016Journal article Open access
Simple item page
dc.contributor.authorSemelka, RC
dc.contributor.authorRamalho, J
dc.contributor.authorVakharia, A
dc.contributor.authorAlObaidy, M
dc.contributor.authorBurke, LM
dc.contributor.authorJay, M
dc.contributor.authorRamalho, M
dc.date.accessioned2018-03-15T15:28:26Z
dc.date.available2018-03-15T15:28:26Z
dc.date.issued2016
dc.description.abstractPURPOSE: To describe the clinical manifestations of presumed gadolinium toxicity in patients with normal renal function. MATERIALS AND METHODS: Participants were recruited from two online gadolinium toxicity support groups. The survey was anonymous and individuals were instructed to respond to the survey only if they had evidence of normal renal function, evidence of gadolinium in their system beyond 30days of this MRI, and no pre-existent clinical symptoms and/or signs of this type. RESULTS: 42 subjects responded to the survey (age: 28-69, mean 49.1±22.4years). The most common findings were: central pain (n=15), peripheral pain (n=26), headache (n=28), and bone pain (n=26). Only subjects with distal leg and arm distribution described skin thickening (n=22). Clouded mentation and headache were the symptoms described as persistent beyond 3months in 29 subjects. Residual disease was present in all patients. Twenty-eight patients described symptoms following administration of one brand of Gadolinium-Based Contrast Agent (GBCA), 21 after a single GBCA administration and 7 after multiple GBCA administrations, including: gadopentetate dimeglumine, n=9; gadodiamide, n=4; gadoversetamide, n=4; gadobenate dimeglumine, n=4; gadobutrol, n=1; gadoteridol, n=2; and unknown, n=4. CONCLUSIONS: Gadolinium toxicity appears to arise following GBCA administration, which appears to contain clinical features seen in Nephrogenic Systemic Fibrosis, but also features not observed in that condition.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMagn Reson Imaging. 2016 Dec;34(10):1383-1390pt_PT
dc.identifier.doi10.1016/j.mri.2016.07.016pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/2952
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.subjectAdultpt_PT
dc.subjectAgedpt_PT
dc.subjectContrast Mediapt_PT
dc.subjectFemalept_PT
dc.subjectGadoliniumpt_PT
dc.subjectGadolinium DTPApt_PT
dc.subjectHeterocyclic Compoundspt_PT
dc.subjectHumanspt_PT
dc.subjectMalept_PT
dc.subjectMegluminept_PT
dc.subjectMiddle Agedpt_PT
dc.subjectOrganometallic Compoundspt_PT
dc.subjectPainpt_PT
dc.subjectProspective Studiespt_PT
dc.subjectMagnetic Resonance Imagingpt_PT
dc.subjectCHLC IMApt_PT
dc.titleGadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a Whilept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage1390pt_PT
oaire.citation.issue10pt_PT
oaire.citation.startPage1383pt_PT
oaire.citation.titleMagnetic Resonance Imagingpt_PT
oaire.citation.volume34pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Magnetic reson Imag 2016 1383.pdf
Size:
1.77 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

IMA - Artigos